Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy
W Ge, Y Dong, Y Deng, L Chen, J Chen, M Liu… - Frontiers in …, 2022 - frontiersin.org
Tumor-specific T cells (TSTs) are essential components for the success of personalized
tumor-infiltrating lymphocyte (TIL)-based adoptive cellular therapy (ACT). Therefore, the …
tumor-infiltrating lymphocyte (TIL)-based adoptive cellular therapy (ACT). Therefore, the …
Nivolumab reaches brain lesions in patients with recurrent glioblastoma and induces T-cell activity and upregulation of checkpoint pathways
SK Skadborg, S Maarup, A Draghi, A Borch… - Cancer immunology …, 2024 - aacrjournals.org
Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis. Although
immunotherapy is being explored as a potential treatment option for patients with GBM, it is …
immunotherapy is being explored as a potential treatment option for patients with GBM, it is …
Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Purpose: Impaired MHCI-presentation and insensitivity to immune effector molecules are
common features of immune checkpoint blockade (ICB)-resistant tumors and can be …
common features of immune checkpoint blockade (ICB)-resistant tumors and can be …
What do cancer-specific T cells 'see'?
S Shah, A Al-Omari, KW Cook, SJ Paston… - Discovery …, 2023 - academic.oup.com
Complex cellular interactions between the immune system and cancer can impact tumour
development, growth, and progression. T cells play a key role in these interactions; however …
development, growth, and progression. T cells play a key role in these interactions; however …
The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women
J Meng, JYT Tan, CR Joseph, J Ye, JCT Lim… - Laboratory …, 2024 - Elsevier
Triple-negative breast cancer (TNBC) has a poor prognosis with limited therapeutic options
available for affected patients. Efforts are ongoing to identify surrogate markers for tumor …
available for affected patients. Efforts are ongoing to identify surrogate markers for tumor …
A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer
Background Molecular profiling of the tumour immune microenvironment (TIME) has
enabled the rational choice of immunotherapies in some adult cancers. In contrast, the TIME …
enabled the rational choice of immunotherapies in some adult cancers. In contrast, the TIME …
[HTML][HTML] Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma
SK Mørk, SK Skadborg, B Albieri, A Draghi… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Original research: Dose escalation study of a personalized peptide-based neoantigen vaccine
(EVX-01) in patients with metastatic melanoma - PMC Back to Top Skip to main content NIH …
(EVX-01) in patients with metastatic melanoma - PMC Back to Top Skip to main content NIH …
Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system
C Völzke, L Ehrhardt, L Fischer, P Maul… - Frontiers in …, 2024 - frontiersin.org
Recent studies have revealed the potential of tumor-infiltrating lymphocytes (TILs) to treat
solid tumors effectively and safely. However, the translation of TIL therapy for patients is still …
solid tumors effectively and safely. However, the translation of TIL therapy for patients is still …
CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy
B Thompson, A Strange, CM Amato… - The Journal of …, 2023 - journals.aai.org
Tumor-infiltrating lymphocyte (TIL) adoptive cell therapy is effective in treating malignant
melanoma, but its success relies on the adequate ex vivo expansion of TIL. To assess …
melanoma, but its success relies on the adequate ex vivo expansion of TIL. To assess …
Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T …
CH Fang, WF Cheng, YF Cheng, KL Lan, JM Lee - BMC cancer, 2024 - Springer
Background Although immune cell therapy has long been used for treating solid cancer, its
efficacy remains limited. Interferon (IFN)-producing killer dendritic cells (IKDCs) exhibit …
efficacy remains limited. Interferon (IFN)-producing killer dendritic cells (IKDCs) exhibit …